Phenotypes, investigation and treatment of primary IGF-1 deficiency

Hormone Resistance and Hypersensitivity: From Genetics to Clinical Management

Volumn 24, Issue , 2013, Pages 138-149

  Savage, Martin O ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84925804191     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000342578     Document Type: Chapter

References (26)

1. Laron Z: Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958-2003. J Clin Endocrinol Metab 2004; 89:1031-1044.
2. Eshet R, Laron Z, Pertzelan A, Arnon R, Dintzman M: Defect of human growth hormone receptors in the liver of two patients with Laron-type dwarfism. Isr J Med Sci 1984;20:8-11.
3. Laron Z, Klinger B, Erster B, Anin S: Effect of acute administration of insulin-like growth factor I in patients with Laron-type dwarfism. Lancet 1988; 2:1170-1172.
4. Godowski PJ, Leung DW, Meacham LR, Galgani JP, Hellmiss R, Keret R, Rotwein PS, Parks JS, Laron Z, Wood WI: Characterization of the human growth hormone receptor gene and demonstration of a partial gene deletion in two patients with Larontype dwarfism. Proc Natl Acad Sci U S A 1989;86: 8083-8087.
5. Salmon WD Jr, Daughaday WH: A hormonally controlled serum factor which stimulates sulphate incorporation by cartilage in vitro. J Lab Clin Med 1957;49:825-836.
6. Green H, Morikawa M, Nixon T: A dual effector theory of growth-hormone action. Differentiation 1985;29:195-198.
7. Isaksson OG, Jansson JO, Gause IA: Growth hormone stimulates longitudinal bone growth directly. Science 1982;216:1237-1239.
8. Nilsson A, Isgaard J, Lindahl A, Dahlstrom A, Skottner A, Isaksson OG: Regulation by growth hormone of number of chondrocytes containing IGF-I in rat growth plate. Science 1986;233:571-574.
9. Le Roith D, Bondy C, Yakar S, Liu JL, Butler A: The somatomedin hypothesis: 2001. Endocr Rev 2001; 22:53-74.
10. Ohlsson C, Mohan S, Sjögren K, Tivesten A, Isgaard J, Isaksson O, Jansson JO, Svensson J: The role of liver-derived insulin-like growth factor-I. Endocr Rev 2009;30:494-535.
11. Domené HM, Bengolea SV, Martínez AS, Ropelato MG, Pennisi P, Scaglia P, Heinrich JJ, Jasper HG: Deficiency of the circulating insulin-like growth factor system associated with inactivation of the acid-labile subunit gene. N Engl J Med 2004;350: 570-577.
12. David A, Hwa V, Metherell LA, Netchine I, Camacho-Hübner C, Clark AJL, Rosenfeld RG, Savage MO: Evidence for a continuum of genetic, phenotypic and biochemical abnormalities in children with growth hormone insensitivity. Endocr Rev 2011;32:472-497.
13. Fowden AL: The insulin-like growth factors and feto-placental growth. Placenta 2003;24:803-812.
14. Woods KA, Camacho-Hübner C, Savage MO, Clark AJL: Intrauterine growth retardation and post-natal growth failure associated with deletion of the insulin-like growth factor-I gene. N Engl J Med 1996;335:1363-1367.
15. Netchine I, Azzi S, Le Bouc Y, Savage MO: IGF1 molecular anomalies demonstrate its critical role in fetal, postnatal growth and brain development. Best Pract Res Clin Endocrinol Metab 2011;25:181-190.
16. Woods KA, Dastot F, Preece MA, Clark AJL, Postel-Vinay MC, Chatelain PG, Ranke MB, Rosenfeld RG, Amselem S, Savage MO: Phenotype: genotype relationships in growth hormone insensitivity syndrome. J Clin Endocrinol Metab 1997;82:3529-3535.
17. Ayling RM, Ross R, Towner P, Von Laue S, Finidori J, Moutoussamy S, Buchanan CR, Clayton PE, Norman MR: A dominant-negative mutation of the growth hormone receptor causes familial short stature. Nat Genet 1997;16:3-14.
18. Metherell LA, Akker SA, Munroe PB, Rose SJ, Caulfield M, Savage MO, Chew SL, Clark AJL: Pseudoexon activation as a novel mechanism for disease resulting in atypical growth hormone insensitivity. Am J Hum Genet 2001;69:641-646.
19. Domené HM, Hwa V, Argente J, Wit JM, Camacho-Hübner C, Jasper HG, Pozo J, van Duyvenvoorde HA, Yakar S, Fofanova-Gambetti OV, Rosenfeld RG; International ALS Collaborative Group: Human acid-labile subunit deficiency: clinical, endocrine and metabolic consequences. Horm Res Pediatr 2009;72:129-141.
20. Rosenfeld RG, Belgorosky A, Camacho-Hubner C, Savage MO, Wit JM, Hwa V: Defects in growth hormone receptor signaling. Trends Endocrinol Metab 2007;18:134-141.
21. Juul A, Bang P, Hertel NT, Main K, Dalgaard P, Jørgensen K, Müller J, Hall K, Skakkebaek NE: Serum insulin-like growth factor-I in 1030 healthy children, adolescents and adults: relation to age, sex, stage of puberty, testicular size and body mass index. J Clin Endocrinol Metab 1994;78:744-752.
22. Coutant R, Dörr HG, Gleeson H, Argente J: Limitations of the IGF-I generation test in children with short stature. Eur J Endocrinol 2011;166:351-357.
23. Fofanova-Gambetti OV, Hwa V, Wit JM, Domene HM, Argente J, Bang P, Högler W, Kirsch S, Pihoker C, Chiu HK, Cohen L, Jacobsen C, Jasper HG, Haeusler G, Campos-Barros A, Gallego-Gómez E, Gracia-Bouthelier R, van Duyvenvoorde HA, Pozo J, Rosenfeld RG: Impact of heterozygosity for acidlabile subunit (IGFALS) gene mutations on stature: results from the international acid-labile subunit consortium. J Clin Endocrinol Metab 2010;95:4184-4191.
24. Midyett LK, Rogol AD, Frane J, Bright GM: Recombinant insulin-like growth factor (IGF)-I treatment in short children with low IGF-I levels: first-year results from a randomised clinical trial J Clin Endocrinol Metab 2009;95:611-619.
25. Ranke MB, Savage MO, Chatelain PG, Preece MA, Rosenfeld RG, Wilton P: Long-term treatment of growth hormone insensitivity syndrome with IGFI. Results of the European Multicentre Study. The Working Group on Growth Hormone Insensitivity Syndromes. Horm Res 1999;51:128-134.
26. Chernausek SD, Backeljauw PF, Frane J, Kuntze J, Underwood LE: Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrinol Metab 2007;92:902-910.